Literature DB >> 23763774

The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.

K Shiomitsu1, E Sajo2, C Rubin1, I Sehgal3.   

Abstract

ENMD-2076 is an aurora kinase inhibitor that also has multi-target tyrosine kinase inhibitor properties. In this study, the mRNA and the protein expression of aurora-A and aurora-B were evaluated in three canine mast cell tumour cell lines. Dose-dependent cytotoxicity was seen in the cells treated, and it affected the cell cycle with cells in the G2/M phase being selectively killed. The cells were also evaluated for radiosensitivity with/without ENMD-2076, and radiosensitization was seen after 3 Gy and 6 Gy exposures with ENMD-2076 for 48 h. Protein expression of caspase-3 was gradually increased, and the expression intensity was highest at 24 h post irradiation in cells without ENMD-2076 treatment, which indicates that radiation exposure with ENMD-2076-induced cell death faster than radiation treatment alone. Our study results suggest the potential usefulness of treating canine mast cell tumours with aurora kinase inhibitors alone or in conjunction with radiation therapy.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  ENMD-2076; aurora kinase inhibitors; canine mast cell tumours; radiosensitivity

Mesh:

Substances:

Year:  2013        PMID: 23763774      PMCID: PMC3812382          DOI: 10.1111/vco.12046

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  47 in total

1.  Establishment and characterization of a new canine mast cell tumor cell line.

Authors:  T Ishiguro; T Kadosawa; K Mori; S Takagi; M Okumura; T Fujinaga
Journal:  J Vet Med Sci       Date:  2001-09       Impact factor: 1.267

2.  Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.

Authors:  J J Thompson; J A Yager; S J Best; D L Pearl; B L Coomber; R N Torres; M Kiupel; R A Foster
Journal:  Vet Pathol       Date:  2010-12-15       Impact factor: 2.221

3.  Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.

Authors:  Xiaojing Wang; Anthony L Sinn; Karen Pollok; George Sandusky; Shuhong Zhang; Li Chen; Jing Liang; Colin D Crean; Attaya Suvannasankha; Rafat Abonour; Carolyn Sidor; Mark R Bray; Sherif S Farag
Journal:  Br J Haematol       Date:  2010-06-15       Impact factor: 6.998

4.  Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.

Authors:  Ryan P Fulcher; Lori L Ludwig; Philip J Bergman; Shelley J Newman; Amelia M Simpson; Amiya K Patnaik
Journal:  J Am Vet Med Assoc       Date:  2006-01-15       Impact factor: 1.936

5.  Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications.

Authors:  Eugenia García-Fernández; Juan I De Diego; Elena Collantes-Bellido; Marta Mendiola; María P Prim; Elia Pérez-Fernández; María Miguel-Martín; Manuel Nistal; David Hardisson
Journal:  Histopathology       Date:  2011-02-07       Impact factor: 5.087

6.  Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours.

Authors:  G A Maglennon; S Murphy; V Adams; J Miller; K Smith; A Blunden; T J Scase
Journal:  Vet Comp Oncol       Date:  2008-12       Impact factor: 2.613

7.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.

Authors:  Jing Yang; Takayuki Ikezoe; Chie Nishioka; Taizo Tasaka; Ayuko Taniguchi; Yoshio Kuwayama; Naoki Komatsu; Kentaro Bandobashi; Kazuto Togitani; H Phillip Koeffler; Hirokuni Taguchi; Akihito Yokoyama
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

8.  Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer.

Authors:  Yasmine Nadler; Robert L Camp; Candice Schwartz; David L Rimm; Harriet M Kluger; Yuval Kluger
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

9.  Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.

Authors:  Felix Keil; Edgar Selzer; Andrea Berghold; Sabine Reinisch; Karin S Kapp; Alexander De Vries; Richard Greil; Barbara Bachtiary; Christoph Tinchon; Wolfgang Anderhuber; Martin Burian; Anne-Katrin Kasparek; Wolfgang Elsäßer; Herbert Kainz; Regina Riedl; Michael Kopp; Gabriela Kornek
Journal:  Eur J Cancer       Date:  2012-09-14       Impact factor: 9.162

10.  Aurora kinases as prognostic biomarkers in ovarian carcinoma.

Authors:  Marta Mendiola; Jorge Barriuso; Adrián Mariño-Enríquez; Andrés Redondo; Aurora Domínguez-Cáceres; Ginés Hernández-Cortés; Elia Pérez-Fernández; Iker Sánchez-Navarro; Juan Angel Fresno Vara; Asunción Suárez; Enrique Espinosa; Manuel González-Barón; José Palacios; David Hardisson
Journal:  Hum Pathol       Date:  2009-01-20       Impact factor: 3.466

View more
  4 in total

Review 1.  Insights into the non-mitotic functions of Aurora kinase A: more than just cell division.

Authors:  Giulia Bertolin; Marc Tramier
Journal:  Cell Mol Life Sci       Date:  2019-09-27       Impact factor: 9.261

2.  Aurora-A affects radiosenstivity in cervical squamous cell carcinoma and predicts poor prognosis.

Authors:  Yuhua Ma; Jie Yang; Ruozheng Wang; Zegao Zhang; Xiaoli Qi; Chunhua Liu; Miaomiao Ma
Journal:  Oncotarget       Date:  2017-05-09

3.  Aurora-A Induces Chemoresistance Through Activation of the AKT/mTOR Pathway in Endometrial Cancer.

Authors:  Jun Wu; Ziyun Cheng; Xiaofeng Xu; Jian Fu; Kaiyue Wang; Tao Liu; Chan Wu; Xiangyi Kong; Qian Yang; Guijun Yan; Huaijun Zhou
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

Review 4.  Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy.

Authors:  Ruijuan Du; Chuntian Huang; Kangdong Liu; Xiang Li; Zigang Dong
Journal:  Mol Cancer       Date:  2021-01-15       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.